Rein Therapeutics Inc. (NASDAQ:RNTX) Short Interest Update

Rein Therapeutics Inc. (NASDAQ:RNTX) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 441,027 shares, an increase of 25.5% from the January 15th total of 351,493 shares. Approximately 1.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 140,201 shares, the days-to-cover ratio is presently 3.1 days. Based on an average daily trading volume, of 140,201 shares, the days-to-cover ratio is presently 3.1 days. Approximately 1.8% of the shares of the stock are short sold.

Rein Therapeutics Stock Performance

Shares of NASDAQ RNTX traded down $0.05 during mid-day trading on Monday, reaching $1.12. 84,753 shares of the company traded hands, compared to its average volume of 108,131. Rein Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $2.96. The company’s fifty day moving average is $1.28 and its two-hundred day moving average is $1.29. The stock has a market cap of $29.44 million, a PE ratio of -0.43 and a beta of 1.48.

Rein Therapeutics (NASDAQ:RNTX) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03. Research analysts forecast that Rein Therapeutics will post -1.56 earnings per share for the current year.

Hedge Funds Weigh In On Rein Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp boosted its holdings in Rein Therapeutics by 374.3% in the 4th quarter. State Street Corp now owns 75,904 shares of the company’s stock valued at $88,000 after purchasing an additional 59,900 shares during the period. Voss Capital LP raised its position in shares of Rein Therapeutics by 59.2% during the fourth quarter. Voss Capital LP now owns 4,243,969 shares of the company’s stock valued at $4,923,000 after buying an additional 1,577,437 shares during the last quarter. Gagnon Securities LLC lifted its stake in shares of Rein Therapeutics by 5.0% in the fourth quarter. Gagnon Securities LLC now owns 240,220 shares of the company’s stock valued at $279,000 after buying an additional 11,528 shares during the period. Jane Street Group LLC acquired a new stake in Rein Therapeutics during the fourth quarter worth about $72,000. Finally, HRT Financial LP bought a new position in Rein Therapeutics during the fourth quarter valued at about $38,000. Institutional investors own 90.89% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Citigroup lowered shares of Rein Therapeutics to a “hold” rating in a report on Wednesday, January 21st. Loop Capital set a $6.00 price objective on shares of Rein Therapeutics in a research note on Monday, November 3rd. Brookline Capital Acquisition downgraded shares of Rein Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. Weiss Ratings restated a “sell (e+)” rating on shares of Rein Therapeutics in a report on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of Rein Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, December 14th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $8.00.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.